Evidence map›Paper›PMID 29785135›Full record

ArticleThe application of clinical genetics2018

Mutation analysis of BRCA1/2 mutations with special reference to polymorphic SNPs in Indian breast cancer patients.

Nidhi D Shah, Parth S Shah, Yash Y Panchal, Kalpesh H Katudia, Nikunj B Khatri, Hari Shankar P Ray, Upti R Bhatiya, Sandip C Shah, Bhavini S Shah, Mandava V Rao

Open access · goldAbstract read
In one paragraph

Article in The application of clinical genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. The Journal of international medical research · 2022
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Development of an AmpliSeqFrontiers in pharmacology · 2018
    Article
  10. GermlineCancer management and research · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Nidhi D ShahDepartment of Pediatrics, Nassau University Medical Center, New York City, NY, USA.
Parth S ShahDepartment of Medicine, Lahey Hospital and Medical Center, Boston, MA, USA.
Yash Y PanchalSupratech Micropath Laboratory and Research Institute, Ahmedabad, Gujarat, India.
Kalpesh H KatudiaSupratech Micropath Laboratory and Research Institute, Ahmedabad, Gujarat, India.
Nikunj B KhatriSupratech Micropath Laboratory and Research Institute, Ahmedabad, Gujarat, India.
Hari Shankar P RaySupratech Micropath Laboratory and Research Institute, Ahmedabad, Gujarat, India.
Upti R BhatiyaSupratech Micropath Laboratory and Research Institute, Ahmedabad, Gujarat, India.
Sandip C ShahSupratech Micropath Laboratory and Research Institute, Ahmedabad, Gujarat, India.
Bhavini S ShahDepartment of Pediatrics, Nassau University Medical Center, New York City, NY, USA.
Mandava V RaoSchool of Sciences, Gujarat University, Ahmedabad, Gujarat, India.
Gujarat Institute of Development Research · INNassau University Medical Center · USGujarat University · INLahey Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGermline mutations BRCA1 and BRCA2 contribute almost equally in the causation of breast cancer (BC). The type of mutations in the Indian population that cause this condition is largely unknown. PURPOSE: In this cohort, 79 randomized BC patients were screened for various types of BRCA1 and BRCA2 mutations including frameshift, nonsense, missense, in-frame and splice site types. MATERIALS AND

methodsThe purified extracted DNA of each referral patient was subjected to Sanger gene sequencing using Codon Code Analyzer and Mutation Surveyor and next-generation sequencing (NGS) methods with Ion torrent software, after appropriate care.

resultsThe data revealed that 35 cases were positive for BRCA1 or BRCA2 (35/79: 44.3%). BRCA2 mutations were higher (52.4%) than BRCA1 mutations (47.6%). Five novel mutations detected in this study were p.pro163 frameshift, p.asn997 frameshift, p.ser148 frameshift and two splice site single-nucleotide polymorphisms (SNPs). Additionally, four nonsense and one in-frame deletion were identified, which all seemed to be pathogenic. Polymorphic SNPs contributed the highest percentage of mutations (72/82: 87.8%) and contributed to pathogenic, likely pathogenic, likely benign, benign and variant of unknown significance (VUS). Young age groups (20-60 years) had a high frequency of germline mutations (62/82;75.6%) in the Indian population.

conclusionThis study suggested that polymorphic SNPs contributed a high percentage of mutations along with five novel types. Younger age groups are prone to having BC with a higher mutational rate. Furthermore, the SNPs detected in exons 10, 11 and 16 of BRCA1 and BRCA2 were higher than those in other exons 2, 3 and 9 polymorphic sites in two germline genes. These may be contributory for BC although missense types are known to be susceptible for cancer depending on the type of amino acid replaced in the protein and associated with pathologic events. Accordingly, appropriate counseling and treatment may be suggested.

Indexed as

ageBRCA1 and BRCA2 gene mutationsbreast cancerNGSnovel typespolymorphic SNPsSanger gene sequencer

Identifiers

PMID29785135
PMCPMC5953318
OpenAlexW2801477597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.